Return to homepagePandemic Pact

Recoding the SARS-CoV-2 genome - A multidisciplinary approach to generate live-attenuated coronavirus vaccines

  • Funded by State Secretariat for Education, Research and Innovation (SERI)
  • Total publications:0 publications

Grant number: 7270341

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2022

  • Known Financial Commitments (USD)

    $2,565,896.46

  • Funder

    State Secretariat for Education, Research and Innovation (SERI)

  • Principal Investigator

    Thiel Volker

  • Research Location

    N/A

  • Lead Research Institution

    N/A

  • Research Priority Alignment

    N/A

  • Research Category

    Vaccines research, development and implementation

  • Research Subcategory

    Characterisation of vaccine-induced immunity

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Compared to the first generation vaccines, the vaccine differs in four ways. It offers a longer-term immune response that is created by the activation of T cells. The vaccine is effective despite mutations of the coronavirus spike protein because it contains all viral proteins and not just the spike protein. In addition, nasal administration in the form of a nasal spray is possible and the vaccine remains stable even at higher temperatures.